The I-O Movement: Priming the Immune System to Fight Cancer – Part I: Chimeric Antigen Receptor T (CAR-T) Cell Technology
There has been a lot of recent buzz about chimeric antigen receptor (CAR) T cell technology. Novartis and Gilead have FDA-approved CAR-T therapies offering complete patient remission from certain cancers. A flood of new CAR-based technologies is likely to hit the market. As with any novel therapy, patent protection is essential. The large number of patent filings suggest that intellectual property protection is an important part of the research efforts in this field. The bolded patent documents cited in this article are further summarized in the table at the end of this installment.